stockrow
Monday 9 November 2026
Export ACOG’s income statement to Excel — free account
Alpha Cognition Inc.
ACOGAlpha Cognition Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.2 million.
- Revenue
- +267.6%
- EPS
- +51.2%
- Free cash flow
- −109.3%
Quarter to June 2026, against a year earlier
8.29
0.14
+1.72%
Follow ACOG
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 10 | 15 | — | 26 | 48 | 83 | +100.9% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | 81.26 | 90.37 | — | ||||||
| EBT | — | — | — | (7) | (6) | (20) | (12) | (14) | (15) | (21) | (21) | +20.9% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (202.24) | (137.69) | (202.2) pt | ||||||
| Net income | — | — | — | (7) | (6) | (20) | (12) | (14) | (15) | (21) | (21) | +20.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.58 | 0.70 | n/m | |||||
| Earnings | — | — | — | (5.25) | (3.37) | (9.25) | (4.50) | (3.75) | (2.02) | (1.17) | (0.96) | (22.1%) | ||||||
| Cash flow | — | — | — | (2.03) | (3.17) | (4.63) | (3.40) | (2.45) | (1.07) | (1.15) | (1.42) | (9.0%) | ||||||
| Capex | — | — | — | 0.00 | (0.01) | (0.03) | 0.00 | 0.00 | 0.00 | (0.02) | (0.29) | n/m | ||||||
| Free cash flow | — | — | — | (2.03) | (3.17) | (4.66) | (3.40) | (2.45) | (1.07) | (1.17) | (1.70) | (8.8%) | ||||||
| Book value | — | — | — | 4.17 | 0.01 | 4.23 | (0.49) | (1.31) | 5.39 | 3.54 | 2.43 | (2.7%) | ||||||
| Shares, m | — | — | — | 1 | 2 | 2 | 3 | 4 | 7 | 18 | 19 | +55.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | 11.24 | 11.83 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | 1.84 | 3.41 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 4.87 | 9.18 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (2.40) | (3.78) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (3) | (5) | (10) | (9) | (9) | (8) | (20) | (31) | +41.4% | |||||
| Capex | — | — | — | — | 0 | 0 | 0 | — | 0 | 0 | (6) | +99.9% | ||||||
| Free cash flow | — | — | — | (3) | (5) | (10) | (9) | (9) | (8) | (21) | (37) | +41.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 5 | 4 | 10 | (2) | (1) | 47 | 70 | 52 | +53.9% | |||||
| Net debt | — | — | — | (5) | (3) | (11) | (2) | (1) | (49) | (66) | (41) | +55.6% | ||||||
| Shareholders’ equity | — | — | — | 5 | 0 | 9 | (1) | (5) | 39 | 63 | 53 | +51.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (78.00) | (183.38) | (153.05) | (509.46) | (55.61) | (31.69) | (38.33) | (31.7) pt | |||||
| ROIC | — | — | — | (685.00) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (144.65) | +685.0 pt | ||||||
| ROE | — | — | — | 0.00 | (219.92) | (432.14) | (314.28) | 456.96 | (86.00) | (40.68) | (49.53) | (40.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 57 | 71 | — | +24.6% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.14 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Alpha Cognition Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TRDA Entrada Therapeutics, Inc. | $191.5M | — (loss-making) | — (loss-making) | −43.93% (below 0%: shrinking) | n/m | −7.05% (below 0%: shrinking) | 100.00% | (4,606.52%) | Compare |
| CGEN Compugen Ltd. | $185.7M | 5.2× | — (loss-making) | +107.00% (above 0%: growing) | n/m | −155.42% (below 0%: shrinking) | (3.54%) | (339.62%) | Compare |
| MDWD MediWound Ltd. | $184.0M | — (loss-making) | — (loss-making) | −45.83% (below 0%: shrinking) | n/m | −49.90% (below 0%: shrinking) | 10.90% | (305.89%) | Compare |
| BCYC Bicycle Therapeutics PLC Sponsored ADR | $182.5M | — (loss-making) | — (loss-making) | +190.24% (above 0%: growing) | n/m | +43.48% (above 0%: growing) | 100.00% | (39.57%) | Compare |
| ACOG Alpha Cognition Inc. | $180.5M | — (loss-making) | — (loss-making) | +267.56% (above 0%: growing) | n/m | −109.25% (below 0%: shrinking) | 94.80% | (127.29%) | |
| WHWK Whitehawk Therapeutics, Inc. | $178.4M | — (loss-making) | — (loss-making) | +33.48% (above 0%: growing) | n/m | +72.57% (above 0%: growing) | 89.36% | 0.00% | Compare |
| UPB Upstream Bio, Inc. | $176.9M | — (loss-making) | — (loss-making) | −17.50% (below 0%: shrinking) | n/m | +9.33% (above 0%: growing) | 100.00% | (5,480.98%) | Compare |
| IVVD Invivyd, Inc. | $166.0M | — (loss-making) | — (loss-making) | +21.20% (above 0%: growing) | n/m | −226.89% (below 0%: shrinking) | 91.09% | (320.76%) | Compare |
| BBOT BridgeBio Oncology Therapeutics, Inc | $163.6M | — (loss-making) | — | — | n/m | −88.78% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $180.5M | — | — | +21.20% | — | −28.47% | 91.09% | (313.32%) |
Pay and ownership Proxy statement filed 30 April 2026
Ownership
Directors and executive officers, together
9.50%
Opaleye L.P. One Boston Place,
10.90%
AWM Investment Company Inc.
9.80%
Manchester Management Company, LLC
5.00%
Funicular Funds, LP
5.00%
Ikarian Capital, LLC
4.90%
Ken Cawkell, Director
2.20%
Len Mertz, Chairman of the Board
2.00%
Phillip Mertz, Director
less than 1%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement